Go or no go? Ozanimod and Fintepla await FDA verdicts

Go or no go? Ozanimod and Fintepla await FDA verdicts

Source: 
EP Vantage
snippet: 

Big approval decisions pending in March include ozanimod in multiple sclerosis, where Bristol-Myers is likely to win a green light, while the safety of Zogenix's Fintepla will be scrutinised.